Chongqing Genrix Biopharmaceutical (SH:688443) Xin Lang Cai Jing·2025-10-30 14:10Core Viewpoint - Zhixiang Jintai, established in October 2015 and listed on the Shanghai Stock Exchange in June 2023, focuses on innovative antibody drugs and possesses a strong competitive edge in the innovative drug sector [1] Group 1: Business Overview - The main business of Zhixiang Jintai includes the research, production, and sales of antibody drugs, classified under the pharmaceutical and biological industry [1] - As of Q3 2025, the company reported revenue of 208 million yuan, ranking 30th among 34 companies in the industry, with the industry leader, Changchun High-tech, generating 9.807 billion yuan [2] - The company's net profit for the same period was -333 million yuan, placing it 32nd in the industry, with the top performer, Tonghua Dongbao, reporting a net profit of 1.188 billion yuan [2] Group 2: Financial Performance - As of Q3 2025, Zhixiang Jintai's asset-liability ratio was 41.28%, higher than the industry average of 26.88% [3] - The gross profit margin for the same period was 94.05%, exceeding the industry average of 70.17% [3] Group 3: Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 7.75% to 12,600, while the average number of circulating A-shares held per shareholder decreased by 7.19% to 9,231.01 [5] Group 4: Strategic Developments - On September 22, 2025, the company signed an exclusive cooperation agreement with a subsidiary of Kangzhe Pharmaceutical for two infection-related products, which are in the NDA stage, potentially accelerating market accessibility [6] - The company anticipates significant revenue growth from 2025 to 2027, with projected revenues of 570 million, 890 million, and 1.28 billion yuan, representing year-on-year growth rates of 1781.5%, 57.3%, and 43.8% respectively [6] - The company is focusing on product development quality and has received approval for a second indication for its core product, Saliqi monoclonal antibody [6]